News | August 16, 2021
Glenmark Pharmaceuticals net profit at Rs 306.52 crores in Q1FY22
The company reports revenue growth of 26% and PAT growth of 21% YoY
The company reports revenue growth of 26% and PAT growth of 21% YoY
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
European operations' revenue grew 58.4% to Rs 599.7 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)